Selumetinib NDA Submission for Neurofibromatosis Type 1 (NF1) granted Priority Review
AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration... Read More
AbbVie, Pfizer’s non-exlcusive licencing agreement for biosimilar Humira
Posted on17 Dec 2018
TagsAbbVie, Amgen, biosimilar of sandoz, Boehringer Ingelheim, Fresenius Kabi, humira, Merck, Momenta, Mylan, novartis, Novartis’ Sandoz, Samsung Bioepis, sandoz
Comments0
AbbVie has granted a non-exclusive patent license allowing Pfizer to sell its Humira (adalimumab) biosimilar in many countries around the world, halting... Read More
A close look into: AstraZeneca and Merck’s strategic oncology collaboration
AstraZeneca and Merck & Co., Inc., (Merck; known as MSD outside of the US and Canada) today announced that they have entered... Read More
Merck Licenses Anti-Tau Alzheimer’s Antibody from Teijin Pharma
Posted on29 May 2017
Comments0
Teijin Pharma granted Merck exclusive global rights to develop, manufacture, and commercialize a preclinical-stage anti-tau antibody. Merck says the antibody candidate will... Read More
Eiger BioPharmaceuticals to Develop BMS’ Lambda for HDV
Posted on23 Apr 2016
TagsBristol-Myers Squibb, Eiger BioPharmaceuticals, HDV infection, hepatitis delta virus, Lonafarnib, Merck
Comments0
Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, announced that it has licensed Pegylated Interferon Lambda-1a (Lambda), a novel, well-characterized, first in class... Read More
Merck partners With Harvard to Develop Cancer Treatments
Posted on28 Mar 2016
Tagsacute myeloid leukemia, AML, Matthew Shair, Merck, Merck partners With Harvard to Develop Cancer Treatments
Comments0
Harvard University will partner with Merck & Co. to develop small-molecule treatments for acute myeloid leukemia (AML) and other cancers, in a... Read More
Merck Acquires IOmet Pharma
Merck, known as MSD outside the United States and Canada, announced today that it has acquired IOmet, a privately-held UK-based drug discovery... Read More
Lilly and Merck’s Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA Combination Trial
Eli Lilly and Merck, known as MSD outside the United States and Canada, today announced another immuno-oncology collaboration that will evaluate abemaciclib... Read More